


New generation DES unifies a highly biocompatible platform with drug eluting intelligence:

SEQUENCE - SIMPLY PERFECT.



ANTI-Corrosive
ANTI-Allergic
ANTI-Thrombogenic

Endocor is a global company that develops, manufactures and markets interventional devices for coronary and peripheral application dedicated to supporting the newest technologies and pioneering innovations to improve peoples' lives.

We strive to provide our clients with quality, innovation and superior customer service through product solutions that help manage complications of endovascular disease. We take pride in helping patients prevail over their disease while extending and enhancing their life.

Our innovative Sequence sirolimus eluting coronary stent system is the first carbonized stent (inert carbon technology) with a completely biodegradable polymer coating which contains sirolimus as a highly effective drug for preventing thrombotic and re-stenotic events.


- + **Zero stent thrombosis** during the entire implant period
- + **Drug:** sirolimus (rapamycin)
- + **Coating degradation:** 6 weeks in-vivo
- + **Drug load:** 2.0 $\mu\text{g}/\text{mm}^2$
- + **Polymer:** poly (d, l-lactide-co-glycolid), polyactide 50%, polyglycolid 50%

0%
THROMBOSIS RATE

BENEFITS OF THIS INNOVATIVE TECHNOLOGY

- + Carbon particles become properly incorporated within the atom-lattice
- + Due to high e-negative force carbon particles attract surrounding atoms, like molybdenum and nickel
- + Dissociation of metal particles like nickel or molybdenum is prevented
- + Carbon particles deactivate binding capability of pro-thrombin for sodium
- + Implantation does not show any cracking and peeling
- + Penetration of C⁺-particles is just down to 0.05 μm, whereas coating with C⁺-atoms is 100 fold in thickness

SIGNIFICANTLY LESS NICKEL
RELEASED UNDER IN-VITRO-TEST
CONDITIONS (STRESS-TEST)



0%
THROMBOSIS RATE



SIMPLY
PERFECT
SEQUENCE

DRUG SHORT TERM RELEASE

